Search results
Author(s):
Alberto Corsini
Added:
3 years ago
Premise
Evidence spanning from the pathogenesis of atherosclerosis to epidemiological studies consistently support the direct association of elevated plasma low-density lipoprotein-cholesterol (LDL-C) with the increased risk of cardiovascular disease (CVD). Meta-analysis of 14 trials of statin therapy, with more than 90,000 participants, has shown that each 1mmol/l (39mg/dl) of LDL-C reduction…
View more
Author(s):
Reynaria N Pitts
,
Robert Eckel
Added:
3 years ago
Elevated levels of low-density lipoprotein cholesterol (LDL-C) have long been established as one of the most important risk factors for developing coronary artery disease (CAD) and other forms of atherosclerotic cardiovascular disease (CVD).1,2 Targeting LDL-C reduction has been effective in lowering cardiovascular risk.3,4 The use of HMGCoA reductase inhibitors (statins) for both primary and…
View more
Dyslipidaemia in the Real World
Author(s):
Ricardo Lopez Santi
,
Felipe Martínez
,
Adrian Baranchuk
,
et al
Added:
2 years ago
Article
Author(s):
Stephen J Nicholls
Added:
3 years ago
Therapeutic targeting of dyslipidaemia has been one of the major successes in cardiovascular medicine over the last three decades. On the basis of unequivocal evidence from animal models through to both population and genetic studies in humans, there is a clear association between increasing levels of LDL cholesterol (LDL-C) and incident cardiovascular risk.1 This has prompted efforts to develop…
View more
Author(s):
Pablo Avanzas
Added:
3 years ago
It is a great pleasure for me to introduce the International Society of Cardiovascular Pharmacotherapy (ISCP) section on cardiovascular pharmacotherapy. This issue features a variety of excellent manuscripts on intriguing topics, including the anti-inflammatory effects of curcumin, the effects of statins on T-cell function in acute coronary syndrome in Asian populations, and the cost…
View more
Author(s):
Natalie Koh
,
Brian Ference
,
Stephen J Nicholls
,
et al
Added:
2 years ago
Author(s):
Peter J Lansberg
Added:
3 years ago
The majority of all heart attacks and strokes are observed in individuals without elevated cholesterol levels, and some are in those with low cholesterol. Risk factors are absent in approximately 20% of patients with vascular events. If traditional risk factors seem to be unreliable for predicting events in a large number of individuals, expanding the classic risk prediction model would be the…
View more
Author(s):
Rodrigo Alonso
,
Leopoldo Perez de Isla
,
Ovidio Muñiz-Grijalvo
,
et al
Added:
3 years ago
Familial hypercholesterolaemia (FH) is the genetic disorder most commonly associated with elevated LDL cholesterol (LDL-C) levels from birth and with premature atherosclerotic cardiovascular disease (ASCVD).1 It is caused by mutations in genes related to the clearance of LDLs such as LDL receptor (LDLR), apolipoprotein B-100 (APOB) and proprotein convertase subtilisin/kexin type 9 (PCSK9).2 The…
View more
Author(s):
Antoni Martínez-Rubio
,
Román Freixa Pamias
Added:
3 years ago
Hypercholesterolemia has been known for several years to be a major risk factor in the development of atherosclerosis and consecutively cardiovascular disease. This epidemiological concept has been widely confirmed using different strategies that have reduced low-density lipoprotein (LDL) levels and cardiovascular events (morbidity and mortality) in primary as well as in secondary prevention, in…
View more
Author(s):
Antonio J Vallejo-Vaz
Added:
3 years ago
Elevated LDL cholesterol (LDL-C) plays a major role in the development of atherosclerotic cardiovascular disease (ASCVD). Multiple studies and meta-analyses, including randomised controlled trials, prospective cohort studies and Mendelian randomisation studies, have consistently shown an association between LDL-C and ASCVD risk that is proportional to the magnitude and duration of exposure to…
View more